Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: A randomized, double-blind, and placebo control trial

References

• Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Vildiz BO. The prevalence and features of the polycystic ovary syndrome in unselected population. J Clin Endocrinol Metab 2004;89:2745–2749.
   PubMed Web of Science ®Google Scholar
• Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000;85:2434–2438.
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapanti ED, Bartzis MI. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999;84:4006–4011.
   PubMed Web of Science ®Google Scholar
• Ehrmann D. Polycystic Ovary Syndrome. N Engl J Med 2005;352:1223–1236.
   PubMed Web of Science ®Google Scholar
• Dunaif A. Insulin resistance and polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774–800.
   PubMed Web of Science ®Google Scholar
• Dunaif A, Segal K, Futterweit W, Dobrjansk A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165–1174.
   PubMed Web of Science ®Google Scholar
• Barbieri R, Makris R, Randall R, Daniels G, Kristner R, Ryan KJ. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab 1986;62:904–910.
   PubMed Web of Science ®Google Scholar
• Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, Clore JN, Blackard WG. A direct effect of hyperinsulimemia on serum sex hormone-binding globulin levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1991;72:83–89.
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet P, Shaw J. The IDF Epidemiology Task Force Consensus Group: the metabolic syndrome: a new worldwide definition. Lancet 2005;366:1059–1062.
   PubMed Web of Science ®Google Scholar
• Legro R, Kunselman A, Dodson W, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165–169.
   PubMed Web of Science ®Google Scholar
• Ehrmann D, Barnes R, Rosenfield R, Cavaghan M, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141–146.
   PubMed Web of Science ®Google Scholar
• Legro R, Kunselman A, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 2001;117:607–613.
   Web of Science ®Google Scholar
• Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy PF 2nd, Fitzpatrick LA. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:2562–2568.
   PubMed Web of Science ®Google Scholar
• Wild RA. Long term health consequences of PCOS. Hum Reprod Update 2002;8:231–241.
   PubMed Web of Science ®Google Scholar
• Dahlgren E, Janson PO, Johansson S, Lapidus L, Odén A. Polycystic ovary syndrome and risk for myocardial infarction evaluated from a risk factor model based on a prospective study women. Acta Obstet Gynecol Scand 1992;71:599–604.
   PubMed Web of Science ®Google Scholar
• Talbott E, Clerici A, Berga SL, Kuller L, Guzick D, Detre K, Danielis T, Engberg RA. Adverse lipid and coronary heart risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol 1998;51:415–422.
   PubMed Web of Science ®Google Scholar
• Paradisi G, Steinberg HO, Hempling A, Cronin J, Hook G, Shepard MK, Baron AD. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001;103:1410–1415.
   PubMed Web of Science ®Google Scholar
• Sam S, Duanif A. Polycystic ovary syndrome: syndrome XX? Trends Endocrinol Metab 2003;14:365–370.
   PubMed Web of Science ®Google Scholar
• Lord JM, Flight IH, Norman RJ. Insulin sensitizing drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiroinositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 2003;3: CD003053.
   Google Scholar
• Matthaei S, Stumvoll M, Kellerer M, Haring HU. Pathophysiology and pharmacological treatment of insulin resistance. Endocr Rev 2000;21:585–618.
   PubMed Web of Science ®Google Scholar
• Kirpichnikov D, McFarlane S, Sowers JR. Metformin: an update. Ann Intern Med 2002;137:25–33.
   PubMed Web of Science ®Google Scholar
• Harbone L, Fleming R, Lyall H, Norman J, Sattar N. Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. Lancet 2003;361:1894–1901.
   PubMed Web of Science ®Google Scholar
• Nestler JE. Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med 2008;358:47–54.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Measuring obesity: classification and distribution of anthropometric data. Copenhagen: WHO; 1989 (Nutri UD,EUR/ICP/NUT 125).
   Google Scholar
• Crosignani PG, Colombo M, Vegetti W, Somigliana E, Gessati A, Ragni G. Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Hum Reprod 2003;18:1928–1932.
   PubMed Web of Science ®Google Scholar
• Clark AM, Ledger W, Galletly C, Tomlinson L, Blaney F, Wang X, Norman RJ. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod 1995;10:2705–2712.
   PubMed Web of Science ®Google Scholar
• Hollmann M, Runnebaum B, Gerhard I. Effects of weight loss on the hormonal profile in obese infertile women. Hum Reprod 1996;11:1884–1891.
   PubMed Web of Science ®Google Scholar
• Kiddy DS, Hamilton Fairley D, Bush A, Short F, Anyaoku V, Reed MJ, Franks S. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992;36:105–111.
   PubMed Web of Science ®Google Scholar
• Andersen P, Seljeflot I, Abdelnoor M, Arnesen H, Dale PO, Løvik A, Birkeland K. Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome. Metabolism 1995;44:611–616.
   PubMedGoogle Scholar
• Moran L, Noakes M, Clifton P, Tomlinson L, Norman R. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:812–819.
   PubMed Web of Science ®Google Scholar
• Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994;43:647–654.
   PubMed Web of Science ®Google Scholar
• Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R. The insulin sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996;81:3299–3306.
   PubMed Web of Science ®Google Scholar
• Nestler J, Jakubowicz D. Decreases in ovarian cytochrome P 450c 17α activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996;335:617–623.
   PubMed Web of Science ®Google Scholar
• Jakubowicz D, Nestler J. Lean woman with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian cytochrome P 450c α activity and serum androgens. J Clin Endocrinol Metab 1998;82:4075–4079.
   Google Scholar
• Ehrmann D, Cavaghan M, Imperial J, Sturis J, Rosenfield R, Polonsky K. Effects of metformin on insulin secretion, insulin action and ovarian steroidogenesis in woman with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:524–530.
   PubMed Web of Science ®Google Scholar
• Fleming R, Hopkinson Z, Wallace R. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab 2002;87:569–574.
   PubMed Web of Science ®Google Scholar
• Akbay J, Gundogdu S. Can metformin reduce insulin resistance in polycystic ovary syndrome? Fertil Steril 1996;65:940–949.
   Google Scholar
• Huber-Buchholz M, Carey D, Norman R. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999;84:1470–1474.
   PubMed Web of Science ®Google Scholar
• Després JP, Lemieux I, Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ 2001;322:716–720.
   PubMed Web of Science ®Google Scholar
• Lord JM, Flight IHK, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003;327:951–953.
   PubMed Web of Science ®Google Scholar
• Norman R, Homan G, Moran L, Noakes M. Lifestyle choices, diet, and insulin sensitizers in polycystic ovary syndrome. Endocrine 2006;30:35–43.
   PubMedGoogle Scholar
• Norman R, Davies M, Lord J, Moran L. The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol Metab 2002;13:251–257.
   PubMed Web of Science ®Google Scholar
• Salley K, Wickham E, Cheang K, Essah P, Karjane N, Nestler J. Position statement: glucose intolerance in polycystic ovary syndrome – a position statement of the androgen excess society. J Clin Endocrinol Metab 2007;92:4546–4556.
   PubMed Web of Science ®Google Scholar
• Tang T, Glanville J, Hayden CJ, White D, Barth JH, Balen AH. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome: a randomized, placebo-controlled, double-blind multicenter study. Hum Reprod 2006;21:80–89.
   PubMed Web of Science ®Google Scholar
• Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Collita D, et al Effects of long term treatment with metformin added to hypocaloric diet on body composition, fat distribution and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000;85:139–146.
   PubMedGoogle Scholar